Organon has refuted the allegations made in a complaint filed against it and Sun Pharma USA on July 6. The company stated that the claims and assertions presented in the complaint are entirely meritless. Organon emphasized its position that the legal action lacks substantive basis.

The complaint, which targets Organon and Sun Pharma USA, was lodged on July 6. Organon's response categorically rejects the narrative presented by the plaintiffs. The company maintains that the allegations do not reflect the actual circumstances or conduct of the business.

Organon is prepared to contest the matter vigorously. The company believes the legal proceedings will ultimately demonstrate that the complaints are unfounded. No further financial details or potential impacts were disclosed in the immediate response.

Organon plans to release its second quarter 2026 financial results via a Form 10-Q filing with the Securities and Exchange Commission (SEC). The company also intends to disclose certain non-GAAP financial measures and their reconciliation to comparable GAAP measures in a Form 8-K filing on the same day as the Form 10-Q. During the pendency of the previously announced acquisition by Sun Pharmaceutical Industries Limited on April 26, 2026, Organon has suspended its quarterly earnings calls.

Organon currently expects to record approximately $1 million of milestone expense in the second quarter of 2026. The company’s second quarter results have not been finalized and are subject to its quarterly financial statement closing procedures. There can be no assurance that actual results will not differ from the preliminary estimates described herein.

IPR&D and Milestones

The anticipated milestone expense of $1 million relates to the second quarter of 2026. This figure is preliminary and subject to change pending the completion of the company's quarter-end closing process, including review by management and the audit committee of the board of directors.

About Organon

Organon is a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. With a portfolio of over 70 products across Women’s Health and General Medicines, which includes biosimilars, Organon focuses on addressing health needs that uniquely, disproportionately or differently affect women, while expanding access to essential treatments in over 140 markets. Headquartered in Jersey City, New Jersey, Organon is committed to advancing access, affordability, and innovation in healthcare.